Dexamethasone implant (0.7 mg) in Indian patients with macular edema: Real-life scenario

Taiwan Journal of Ophthalmology

Volumn 8, Issue 3, 2018, Pages 141-148

  Nagpal, Manish ^a   Mehrotra, Navneet ^a   Juneja, Rakesh ^a   Jain, Hardik ^a  

^a Retina Foundation   (India)

Author keywords

Diabetic macular edema; Ozurdex ; posterior segment pathologies; retinal vein occlusion; uveitic macular edema

Indexed keywords

EID: 85053878119     PISSN: 22115056     EISSN: 22115072     Source Type: Journal    
DOI: 10.4103/tjo.tjo_62_17     Document Type: Article

References (14)

1. Wolfensberger TJ, Gregor ZJ. Macular edema-Rationale for therapy. Dev Ophthalmol 2010;47:49-58.
2. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309-17.
3. Sarao V, Veritti D, Boscia F, Lanzetta P. Intravitreal steroids for the treatment of retinal diseases. ScientificWorldJournal 2014;2014:989501.
4. Hadayer A, Schaal S. Delivery of steroids into the eye for the treatment of macular edema. Expert Opin Drug Deliv 2016;13:1083-91.
5. Ozurdex (Dexamethasone Intravitreal Implant 0. 7 mg). [Product monograph]. Markham, ON, Canada: Allergan Inc.; 2015.
6. Mayer WJ, Wolf A, Kernt M, Kook D, Kampik A, Ulbig M, et al. Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion. Eye (Lond) 2013;27:816-22.
7. Lam WC, Albiani DA, Yoganathan P, Chen JC, Kherani A, Maberley DA, et al. Real-world assessment of intravitreal dexamethasone implant (0. 7 mg) in patients with macular edema: The CHROME study. Clin Ophthalmol 2015;9:1255-68.
8. Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: The BEVORDEX study. Ophthalmology 2014;121:2473-81.
9. Chhablani J, Bansal P, Veritti D, Sambhana S, Sarao V, Pichi F, et al. Dexamethasone implant in diabetic macular edema in real-life situations. Eye (Lond) 2016;30:426-30.
10. Totan Y, Güler E, Güraaç FB. Dexamethasone intravitreal implant for chronic diabetic macular edema resistant to intravitreal bevacizumab treatment. Curr Eye Res 2016;41:107-13.
11. Lowder C, Belfort R Jr., Lightman S, Foster CS, Robinson MR, Schiffman RM, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011;129:545-53.
12. Tomkins-Netzer O, Taylor SR, Bar A, Lula A, Yaganti S, Talat L, et al. Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis. Ophthalmology 2014;121:1649-54.
13. Haller JA, Bandello F, Belfort R Jr., Blumenkranz MS, Gillies M, Heier J, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-46.
14. Haller JA, Dugel P, Weinberg DV, Chou C, Whitcup SM. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 2009;29:46-51.